| Phase II study of sorafenib in patients with advanced hepatocellular carcinoma GK Abou-Alfa, L Schwartz, S Ricci, D Amadori, A Santoro, A Figer, ... Journal of clinical oncology 24 (26), 4293-4300, 2006 | 1563 | 2006 |
| Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE‐3 and presented by HLA‐A1 M Marchand, N Van Baren, P Weynants, V Brichard, B Dréno, MH Tessier, ... International journal of cancer 80 (2), 219-230, 1999 | 1112 | 1999 |
| Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses in BRCA Carrier Ovarian Cancer Correlating With Platinum-Free Interval PC Fong, TA Yap, DS Boss, CP Carden, M Mergui-Roelvink, C Gourley, ... Journal of clinical oncology 28 (15), 2512-2519, 2010 | 1107 | 2010 |
| Performance of two geriatric screening tools in older patients with cancer C Kenis, L Decoster, K Van Puyvelde, J De Grève, G Conings, K Milisen, ... J Clin Oncol 32 (1), 19-26, 2014 | 387 | 2014 |
| Phase I study of 68Ga-HER2-nanobody for PET/CT assessment of HER2 expression in breast carcinoma M Keyaerts, C Xavier, J Heemskerk, N Devoogdt, H Everaert, C Ackaert, ... Journal of Nuclear Medicine 57 (1), 27-33, 2016 | 386 | 2016 |
| Adenovirus-mediated wild-type p53 gene transfer in patients receiving chemotherapy for advanced non–small-cell lung cancer: results of a multicenter phase II study M Schuler, R Herrmann, JLP De Greve, AK Stewart, U Gatzemeier, ... Journal of clinical oncology 19 (6), 1750-1758, 2001 | 320 | 2001 |
| miR-146a inhibits cell growth, cell migration and induces apoptosis in non-small cell lung cancer cells G Chen, IA Umelo, S Lv, E Teugels, K Fostier, P Kronenberger, ... PloS one 8 (3), e60317, 2013 | 317 | 2013 |
| Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu J De Greve, E Teugels, C Geers, L Decoster, D Galdermans, J De Mey, ... Lung cancer 76 (1), 123-127, 2012 | 306 | 2012 |
| Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma B Neyns, J Sadones, E Joosens, F Bouttens, L Verbeke, JF Baurain, ... Annals of Oncology 20 (9), 1596-1603, 2009 | 283 | 2009 |
| Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials I Vergote, C Coens, M Nankivell, GB Kristensen, MKB Parmar, T Ehlen, ... The Lancet Oncology 19 (12), 1680-1687, 2018 | 253 | 2018 |
| Catheter tip position as a risk factor for thrombosis associated with the use of subcutaneous infusion ports J Caers, C Fontaine, V Vinh-Hung, J De Mey, G Ponnet, C Oost, J Lamote, ... Supportive Care in Cancer 13, 325-331, 2005 | 222 | 2005 |
| A high proportion of novel mutations in BRCA1 with strong founder effects among Dutch and Belgian hereditary breast and ovarian cancer families T Peelen, M Van Vliet, A Petrij-Bosch, R Mieremet, C Szabo, ... American journal of human genetics 60 (5), 1041, 1997 | 214 | 1997 |
| Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial PY Wen, A Stein, M van den Bent, J De Greve, A Wick, FYFL de Vos, ... The lancet oncology 23 (1), 53-64, 2022 | 202 | 2022 |
| Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal … CH Köhne, J De Greve, JT Hartmann, I Lang, P Vergauwe, K Becker, ... Annals of oncology 19 (5), 920-926, 2008 | 189 | 2008 |
| The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer: results of a phase I study with pharmacokinetics A Awada, F Cardoso, C Fontaine, L Dirix, J De Grève, C Sotiriou, ... European journal of cancer 44 (1), 84-91, 2008 | 181 | 2008 |
| Evaluation of antiandrogen therapy in unresectable hepatocellular carcinoma: results of a European Organization for Research and Treatment of Cancer multicentric double-blind … C Grimaldi, H Bleiberg, F Gay, M Messner, P Rougier, TC Kok, L Cirera, ... Journal of clinical oncology 16 (2), 411-417, 1998 | 166 | 1998 |
| Phase II study of sunitinib malate in patients with recurrent high-grade glioma B Neyns, J Sadones, C Chaskis, M Dujardin, H Everaert, S Lv, J Duerinck, ... Journal of neuro-oncology 103, 491-501, 2011 | 162 | 2011 |
| Safety and efficacy of sorafenib in patients with hepatocellular carcinoma (HCC) and Child-Pugh A versus B cirrhosis GK Abou-Alfa, D Amadori, A Santoro, A Figer, J De Greve, C Lathia, ... Gastrointestinal cancer research: GCR 4 (2), 40, 2011 | 157 | 2011 |
| Efficacy of chemotherapy in BRCA1/2 mutation carrier ovarian cancer in the setting of PARP inhibitor resistance: a multi-institutional study JE Ang, C Gourley, CB Powell, H High, R Shapira-Frommer, ... Clinical Cancer Research 19 (19), 5485-5493, 2013 | 152 | 2013 |
| Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab G Chen, P Kronenberger, E Teugels, IA Umelo, J De Grève BMC medicine 10, 1-15, 2012 | 150 | 2012 |
